NCT06039124View on ClinicalTrials.gov

Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH

CompletedOBSERVATIONAL
Enrollment

23

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

January 1, 2022

Study Completion Date

August 1, 2022

Conditions
Hemorrhagic Hereditary TelangiectasiaHHT
Interventions
OTHER

bevacizumab treatment

Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)

Trial Locations (3)

49933

Service de Médecine Interne et Maladies Vasculaires + Service Neuropédiatrie et neurochirurgie de l'enfant - CHU Angers, Angers

Unknown

Hôpital Ambroise Paré, Boulogne-Billancourt

CHU de Montpellier-Hôpital St Eloi, Montpellier

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT06039124 - Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH | Biotech Hunter | Biotech Hunter